Alnylam Pharmaceuticals (ALNY) Curent Deferred Tax Liability (2014 - 2015)
Alnylam Pharmaceuticals (ALNY) reported Curent Deferred Tax Liability of $9.4 million for Q3 2015, down 52.14% quarter-over-quarter from $19.7 million in Q2 2015.
Alnylam Pharmaceuticals (ALNY) Curent Deferred Tax Liability (2014 - 2015) Analysis & Trends
Alnylam Pharmaceuticals has reported Curent Deferred Tax Liability for 2 years, with the latest figure at $9.4 million in Q3 2015.
- For the quarter ending Q3 2015, Curent Deferred Tax Liability changed N/A year-over-year to $9.4 million; the trailing twelve-month figure through Sep 2015 stood at $9.4 million (changed N/A YoY), and the FY2014 full-year result was $31.7 million, changed N/A from the prior year.
- Curent Deferred Tax Liability for Q3 2015 stood at $9.4 million, down from $19.7 million in the prior quarter.
- The five-year high for Curent Deferred Tax Liability was $33.7 million in Q1 2015, with the low at $9.4 million in Q3 2015.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Curent Deferred Tax (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Alnylam Pharmaceuticals | 37.04 Bn | 34.03 Bn | 959.66 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2015 | 9.41 Mn |
| Sep 30, 2015 | 9.41 Mn |
| Jun 30, 2015 | 19.65 Mn |
| Jun 30, 2015 | 19.65 Mn |
| Mar 31, 2015 | 33.67 Mn |
| Mar 31, 2015 | 33.67 Mn |
| Dec 31, 2014 | 31.67 Mn |
| Dec 31, 2014 | 31.67 Mn |